The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines

References

• Wu AA, Drake V, Huang HS, Chiu S, Zheng L. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology. 2015;4(7):e1016700. doi:10.1080/2162402X.2015.1016700.
   PubMed Web of Science ®Google Scholar
• Caldwell RB, Toque HA, Narayanan SP, Caldwell RW. Arginase: an old enzyme with new tricks. Trends Pharmacol Sci. 2015;36(6):395–16. doi:10.1016/j.tips.2015.03.006.
   PubMed Web of Science ®Google Scholar
• Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat.Rev.Immunol. 2005;5(8):641–654. doi:10.1038/nri1668.
   PubMed Web of Science ®Google Scholar
• Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, Battistini L, Iafrate M, Prayer-Galetti T, Pagano F, et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J.Exp.Med. 2005;201(8):1257–1268. doi:10.1084/jem.20042028.
   PubMed Web of Science ®Google Scholar
• Mondanelli G, Bianchi R, Pallotta MT, Orabona C, Albini E, Iacono A, Belladonna ML, Vacca C, Fallarino F, Macchiarulo A, et al. A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells. Immunity. 2017;46(2):233–244. doi:10.1016/j.immuni.2017.01.005.
   PubMed Web of Science ®Google Scholar
• Gannon PO, Godin-Ethier J, Hassler M, Delvoye N, Aversa M, Poisson AO, Péant B, Alam Fahmy M, Saad F, Lapointe R, et al. Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer. PLoS.One. 2010;5(8):e12107. doi:10.1371/journal.pone.0012107.
   PubMed Web of Science ®Google Scholar
• Cerutti JM, Delcelo R, Amadei MJ, Nakabashi C, Maciel RMB, Peterson B, Shoemaker J, Riggins GJ. A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J.Clin.Invest. 2004;113(8):1234–1242. doi:10.1172/JCI19617.
   PubMed Web of Science ®Google Scholar
• Cerutti JM, Latini FR, Nakabashi C, Delcelo R, Andrade VP, Amadei MJ, Maciel RM, Hojaij FC, Hollis D, Shoemaker J, et al. Diagnosis of suspicious thyroid nodules using four protein biomarkers. Clin Cancer Res. 2006;12(11 Pt 1):3311–3318. doi:10.1158/1078-0432.CCR-05-2226.
   PubMed Web of Science ®Google Scholar
• Bron L, Jandus C, Andrejevic-Blant S, Speiser DE, Monnier P, Romero P, Rivals J-P. Prognostic value of arginase-II expression and regulatory T-cell infiltration in head and neck squamous cell carcinoma. Int.J.Cancer. 2013;132(3):E85–E93. doi:10.1002/ijc.27728.
   PubMed Web of Science ®Google Scholar
• Singh R, Pervin S, Karimi A, Cederbaum S, Chaudhuri G. Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res. 2000;60:3305–3312.
   PubMed Web of Science ®Google Scholar
• Porembska Z, Luboiński G, Chrzanowska A, Mielczarek M, Magnuska J, Barańczyk-Kuźma A. Arginase in patients with breast cancer. Clin.Chim.Acta. 2003;328(1–2):105–111. doi:10.1016/S0009-8981(02)00391-1.
   PubMed Web of Science ®Google Scholar
• Del Ara RM, González-Polo RA, Caro A, Del Amo E, Palomo L, Hernández E, Soler G, Fuentes JM. Diagnostic performance of arginase activity in colorectal cancer. Clin.Exp.Med. 2002;2(1):53–57. doi:10.1007/s102380200007.
   PubMed Web of Science ®Google Scholar
• Takenawa H, Kurosaki M, Enomoto N, Miyasaka Y, Kanazawa N, Sakamoto N, Ikeda T, Izumi N, Sato C, Watanabe M, et al. Differential gene-expression profiles associated with gastric adenoma. Br.J.Cancer. 2004;90(1):216–223. doi:10.1038/sj.bjc.6601399.
   PubMed Web of Science ®Google Scholar
• Mussai F, De Santo C, Abu-Dayyeh I, Booth S, Quek L, McEwen-Smith RM, Qureshi A, Dazzi F, Vyas P, Cerundolo V, et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood. 2013;122(5):749–758. doi:10.1182/blood-2013-01-480129.
   PubMed Web of Science ®Google Scholar
• Mussai F, Egan S, Higginbotham-Jones J, Perry T, Beggs A, Odintsova E, Loke J, Pratt G, U KP, Lo A, et al. Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target. Blood. 2015;125(15):2386–2396. doi:10.1182/blood-2014-09-600643.
   PubMed Web of Science ®Google Scholar
• Monteran L, Erez N. The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front Immunol. 2019;10:1835. doi:10.3389/fimmu.2019.01835.
   PubMed Web of Science ®Google Scholar
• Andersen MH. The balance players of the adaptive immune system. Cancer Res. 2018;78(6):1379–1382. doi:10.1158/0008-5472.CAN-17-3607.
   PubMed Web of Science ®Google Scholar
• Andersen MH. Immune regulation by self-recognition: novel possibilities for anticancer immunotherapy. J Natl Cancer Inst. 2015;107(9):154. doi:10.1093/jnci/djv154.
   Google Scholar
• Martinenaite E, Mortensen REJ, Hansen M, Orebo Holmström M, Munir Ahmad S, Grønne Dahlager Jørgensen N, Met Ö, Donia M, Svane IM, Andersen MH, et al. Frequent spontaneous adaptive immune responses towards arginase. Oncoimmunology. 2017;7(3):e1404215. doi:10.1080/2162402X.2017.1404215.
   PubMed Web of Science ®Google Scholar
• Martinenaite E, Ahmad SM, Svane IM, Andersen MH. Peripheral memory T cells specific for Arginase-1. Cell Mol Immunol. 2019;16(8):718–719. doi: 10.1038/s41423-019-0231-3.
   PubMed Web of Science ®Google Scholar
• Martinenaite E, Ahmad SM, Bendtsen SK, Jørgensen MA, Weis-Banke SE, Svane IM, Andersen MH. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope. Cancer Immunol Immunother. 2019;68(11):1901-1907. doi: 10.1007/s00262-019-02425-6.
   Web of Science ®Google Scholar
• Andersen MH. The targeting of tumor-associated macrophages by vaccination. Cell Stress. 2019;3(5):139–140. doi:10.15698/cst2019.05.185.
   PubMed Web of Science ®Google Scholar
• Henderson RA, Michel H, Sakaguchi K, Shabanowitz J, Appella E, Hunt DF, Engelhard VH. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science. 1992;255(5049):1264–1266. doi: 10.1126/science.1546329.
   Web of Science ®Google Scholar
• Wolfel C, Drexler I, Van Pel A, Thres T, Leister N, Herr W, Sutter G, Huber C, Wölfel T. Transporter (TAP)- and proteasome-independent presentation of a melanoma-associated tyrosinase epitope. Int.J.Cancer. 2000;88(3):432–438. doi:10.1002/1097-0215(20001101)88:3<432::AID-IJC16>3.0.CO;2-9.
   PubMed Web of Science ®Google Scholar
• Martinenaite E, Munir Ahmad S, Hansen M, Met Ö, Westergaard MW, Larsen SK, Klausen TW, Donia M, Svane IM, Andersen MH, et al. CCL22-specific T cells: modulating the immunosuppressive tumor microenvironment. Oncoimmunology. 2016;5(11):e1238541. doi:10.1080/2162402X.2016.1238541.
   PubMed Web of Science ®Google Scholar
• Bonehill A, Heirman C, Tuyaerts S, Michiels A, Breckpot K, Brasseur F, Zhang Y, van der Bruggen P, Thielemans K. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J.Immunol. 2004;172(11):6649–6657. doi:10.4049/jimmunol.172.11.6649.
   PubMed Web of Science ®Google Scholar
• Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int.J.Cancer. 1980;26(2):171–176. doi:10.1002/ijc.2910260208.
   PubMed Web of Science ®Google Scholar
• Chanput W, Mes JJ, Wichers HJ. THP-1 cell line: an in vitro cell model for immune modulation approach. Int.Immunopharmacol. 2014;23(1):37–45. doi:10.1016/j.intimp.2014.08.002.
   PubMed Web of Science ®Google Scholar
• Steube KG, Teepe D, Meyer C, Zaborski M, Drexler HG. A model system in haematology and immunology: the human monocytic cell line MONO-MAC-1. Leuk.Res. 1997;21(4):327–335. doi:10.1016/S0145-2126(96)00129-4.
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel III EE, Koeppen H, Astarita JL, Cubas R, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–548. doi:10.1038/nature25501.
   PubMed Web of Science ®Google Scholar
• Munder M, Eichmann K, Morán JM, Centeno F, Soler G, Modolell M. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J.Immunol. 1999;163:3771–3777.
   PubMed Web of Science ®Google Scholar
• Gotoh T, Sonoki T, Nagasaki A, Terada K, Takiguchi M, Mori M. Molecular cloning of cDNA for nonhepatic mitochondrial arginase (arginase II) and comparison of its induction with nitric oxide synthase in a murine macrophage-like cell line. FEBS Lett. 1996;395(2–3):119–122. doi:10.1016/0014-5793(96)01015-0.
   PubMed Web of Science ®Google Scholar
• Fultang L, Gamble LD, Gneo L, Berry AM, Egan SA, De Bie F, Yogev O, Eden GL, Booth S, Brownhill S, et al. Macrophage-derived IL1beta and TNFalpha regulate arginine metabolism in neuroblastoma. Cancer Res. 2019;79(3):611–624. doi:10.1158/0008-5472.CAN-18-2139.
   PubMed Web of Science ®Google Scholar
• Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu.Rev.Immunol. 2009;27(1):451–483. doi:10.1146/annurev.immunol.021908.132532.451-483.
   PubMed Web of Science ®Google Scholar
• Munir S, Andersen GH, Met O, Donia M, Frosig TM, Larsen SK, Klausen TW, Svane IM, Andersen MH. HLA-restricted cytotoxic T cells that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res. 2013;73(6):1674–1776. doi:10.1158/0008-5472.CAN-12-3507.
   Web of Science ®Google Scholar
• Sorensen RB, Hadrup SR, Svane IM, Hjortsø MC, Thor Straten P, Andersen MH. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood. 2011;117(7):2200–2210. doi:10.1182/blood-2010-06-288498.
   PubMed Web of Science ®Google Scholar
• Sorensen RB, Kollgaard T, Andersen RS, van den Berg JH, Svane IM, Straten PT, Andersen MH. Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2. Cancer Res. 2011;71(6):2038–2044. doi:10.1158/0008-5472.CAN-10-3403.
   PubMed Web of Science ®Google Scholar
• Munir S, Larsen SK, Iversen TZ, Donia M, Klausen TW, Svane IM, Straten PT, Andersen MH. Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase. PLoS One. 2012;7(4):e34568. doi:10.1371/journal.pone.0034568.
   PubMed Web of Science ®Google Scholar
• Munir S, Andersen GH, Svane IM, Andersen MH. The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells. Oncoimmunology. 2013;2(4):e23991. doi:10.4161/onci.23991.
   PubMed Web of Science ®Google Scholar
• Munir S, Andersen GH, Woetmann A, Ødum N, Becker JC, Andersen MH. Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. Leukemia. 2013;27(11):2251–2253. doi:10.1038/leu.2013.118.
   PubMed Web of Science ®Google Scholar
• Munir S, Lundsager MT, Jørgensen MA, Hansen M, Petersen TH, Bonefeld CM, Friese C, Met Ö, Straten PT, Andersen MH, et al. Inflammation induced PD-L1-specific T cells. Cell Stress. 2019;3(10):319–327. doi:10.15698/cst2019.10.201.
   PubMed Web of Science ®Google Scholar
• Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, Ohlfest JR, Hu P, Epstein AL. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J.Immunother. 2013;36(9):477–489. doi:10.1097/01.cji.0000436722.46675.4a.
   PubMed Web of Science ®Google Scholar
• Mosely SI, Prime JE, Sainson RCA, Koopmann J-O, Wang DYQ, Greenawalt DM, Ahdesmaki MJ, Leyland R, Mullins S, Pacelli L, et al. Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery. Cancer Immunol.Res. 2017;5(1):29–41. doi:10.1158/2326-6066.CIR-16-0114.
   PubMed Web of Science ®Google Scholar
• Madsen DH, Jürgensen HJ, Siersbæk MS, Kuczek DE, Grey Cloud L, Liu S, Behrendt N, Grøntved L, Weigert R, Bugge TH, et al. Tumor-associated macrophages derived from circulating inflammatory monocytes degrade collagen through cellular uptake. Cell Rep. 2017;21(13):3662–3671. doi:10.1016/j.celrep.2017.12.011.
   PubMed Web of Science ®Google Scholar
• Met O, Balslev E, Flyger H, Svane IM. High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer. Breast Cancer Res Treat. 2011;125(2):395–406. doi:10.1007/s10549-010-0844-9.
   PubMed Web of Science ®Google Scholar
• Moodie Z, Price L, Janetzki S, Britten CM. Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories. Methods Mol Biol. 2012;792:185–196. doi: 10.1007/978-1-61779-325-7_15.
   PubMedGoogle Scholar